UK in ‘relegation zone’ for prostate cancer survival without screening programme, expert warns.
Dr Letizia Gulino – Head of Science and technology RMDM group
The warning raised by Professor Booth that the United Kingdom risks falling into the European “relegation zone” for prostate cancer survival highlights a reality the British healthcare system can no longer afford to ignore: without a structured early-detection programme, the NHS will inevitably continue diagnosing too many prostate cancers at advanced stages, when therapeutic options become significantly more limited.
In this context, the question is no longer whether innovative early-detection tools should be introduced, but rather how they can be integrated sustainably, effectively, and systemically into the UK diagnostic pathway. At RMDM, webelieve the discussion must move beyond the outdated ideological divide between “traditional screening” and “new technologies” and instead embrace a modern preventive medicine framework based on risk stratification, minimally invasive diagnostics, and optimisation of NHS resources.
Today, the UK faces a clear healthcare paradox: prostate cancer is one of the most common cancers among British men, yet there is still no national organised screening programme. The historical reason is well known. PSA testing, despite decades of use, has demonstrated important limitations related to false positives, overdiagnosis, and overtreatment.
Moreover, the absence of an effective screening strategy has created the opposite, and arguably more dangerous problem: late diagnoses, increased treatment costs, and poorer clinical outcomes.
The scientific landscape has now changed dramatically.
New multimodal screening strategies, combining advanced biomarkers, precision imaging, and risk-based algorithms, are reshaping the global diagnostic paradigm. The TRANSFORM trial promoted by Prostate Cancer UK is itself an institutional acknowledgement that the UK now recognises the urgency of developing a next-generation prostate cancer screening model. It is precisely within this evolving landscape that liquid biopsy technologies such as PanTum Detect® can play a transformative role.
PanTum Detect was not designed to replace clinicians or advanced imaging. It was developed to enable what the NHS currently struggles to achieve: identifying biologically suspicious individuals at a very early stage and selectively directing them toward more advanced and costly diagnostic investigations only when truly necessary.
The innovation behind RMDM’s EDIM/TKTL1-Apo10 technology lies exactly in this systemic approach. Rather than searching for a single organ-specific tumour marker, it detects metabolic and apoptotic alterations associated with oncogenic processes through the analysis of circulating macrophages.
From a strategic perspective for the UK healthcare system, this approach offers at least four critical advantages.
First: sustainability.
The NHS is under unprecedented pressure from diagnostic backlogs, workforce shortages, and rising cancer incidence. A model based exclusively on widespread imaging and invasive biopsies is neither economically nor operationally scalable. A highly specific, minimally invasive blood test can function as an intelligent triage mechanism, reducing unnecessary investigations while concentrating resources on patients with genuine biological risk.
Second: accessibility.
One of the historical limitations of prostate cancer screening has always been patient adherence. Many men present late because they avoid invasive procedures or underestimate symptoms. Liquid biopsy fundamentally changes patient compliance dynamics: a simple annual blood test is culturally and logistically far more acceptable.
Third: integration with modern imaging.
The future is not “blood test versus MRI.” The future is a blood test plus an MRI. The same developments supported by Prostate Cancer UK demonstrate that integration with multiparametric MRI represents the future of intelligent screening. In this model, PanTum Detect can operate as a biological triage tool, directing only high-risk individuals toward advanced imaging pathways, thereby reducing unnecessary procedures, costs, and diagnostic overload.
Fourth: a broader cultural shift.
For decades, oncology systems have focused primarily on treating cancer. The future of medicine must focus on intercepting cancer earlier.
Preventive oncology can no longer remain confined to fragmented, organ-specific screening programmes designed decades ago. Modern oncology is increasingly moving toward MCED (Multi-Cancer Early Detection) strategies built upon systemic biomarkers, integrated diagnostics, and predictive medicine.
Naturally, any innovative technology must undergo rigorous validation, prospective clinical studies, and independent health-economic assessment. No responsible solution should ever be implemented without robust evidence and appropriate regulatory governance. But today, the greatest risk is no longer moving too quickly. The greatest risk is continuing to move too slowly.
If the United Kingdom genuinely wants to escape the “relegation zone” described by Professor Booth, it will need the courage to build a national strategy integrating:
- risk-based screening;
- advanced liquid biopsy;
- precision imaging;
Continuing to rely exclusively on reactive diagnostic models would mean ignoring what science is already making possible. The real question, therefore, is not whether the NHS can afford to introduce innovative early-detection programmes. But it is whether it can afford not to.